CRYSTALLINE FORMS OF CFTR MODULATORS

Crystalline forms of Compound I: Formula (I) pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. L'inv...

Full description

Saved in:
Bibliographic Details
Main Authors ZHOU, Jinglan, MEDEK, Ales, SWIFT, Sara E, HADIDA RUAH, Sara Sabina, PARASELLI, Prasuna, MCCARTNEY, Jason, MILLER, Mark Thomas, FRIEMAN, Bryan, ZWICKER, Carl L, CLEVELAND, Thomas, WALDO, Michael, LU, Jennifer, PIERRE, Fabrice, ANDERSON, Corey Don, LI, Jicong, COON, Timothy Richard, GAGNON, Kevin J, SHI, Yi, ZHANG, Beili, SHRESTHA, Muna, GROOTENHUIS, Peter (deceased), CLEMENS, Jeremy J
Format Patent
LanguageEnglish
French
Published 18.02.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

Abstract Crystalline forms of Compound I: Formula (I) pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. L'invention concerne des formes cristallines du composé I de formule (I), des sels pharmaceutiquement acceptables de celles-ci et des solvates et des hydrates correspondants. L'invention concerne également des compositions pharmaceutiques les comprenant, des procédés de traitement de la mucoviscidose à l'aide de celles-ci et des procédés de fabrication de celles-ci.
AbstractList Crystalline forms of Compound I: Formula (I) pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. L'invention concerne des formes cristallines du composé I de formule (I), des sels pharmaceutiquement acceptables de celles-ci et des solvates et des hydrates correspondants. L'invention concerne également des compositions pharmaceutiques les comprenant, des procédés de traitement de la mucoviscidose à l'aide de celles-ci et des procédés de fabrication de celles-ci.
Author MEDEK, Ales
PIERRE, Fabrice
SHI, Yi
ZHOU, Jinglan
WALDO, Michael
MILLER, Mark Thomas
ZWICKER, Carl L
SHRESTHA, Muna
CLEMENS, Jeremy J
HADIDA RUAH, Sara Sabina
GAGNON, Kevin J
MCCARTNEY, Jason
PARASELLI, Prasuna
SWIFT, Sara E
FRIEMAN, Bryan
GROOTENHUIS, Peter (deceased)
LU, Jennifer
ZHANG, Beili
CLEVELAND, Thomas
LI, Jicong
COON, Timothy Richard
ANDERSON, Corey Don
Author_xml – fullname: ZHOU, Jinglan
– fullname: MEDEK, Ales
– fullname: SWIFT, Sara E
– fullname: HADIDA RUAH, Sara Sabina
– fullname: PARASELLI, Prasuna
– fullname: MCCARTNEY, Jason
– fullname: MILLER, Mark Thomas
– fullname: FRIEMAN, Bryan
– fullname: ZWICKER, Carl L
– fullname: CLEVELAND, Thomas
– fullname: WALDO, Michael
– fullname: LU, Jennifer
– fullname: PIERRE, Fabrice
– fullname: ANDERSON, Corey Don
– fullname: LI, Jicong
– fullname: COON, Timothy Richard
– fullname: GAGNON, Kevin J
– fullname: SHI, Yi
– fullname: ZHANG, Beili
– fullname: SHRESTHA, Muna
– fullname: GROOTENHUIS, Peter (deceased)
– fullname: CLEMENS, Jeremy J
BookMark eNrjYmDJy89L5WRQcQ6KDA5x9PHx9HNVcPMP8g1W8HdTcHYLCVLw9XcJ9XEM8Q8K5mFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8eH-RgZGhgbGBqamRo6GxsSpAgADuSXA
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate FORMES CRISTALLINES DE MODULATEURS DE CFTR
ExternalDocumentID WO2021030552A1
GroupedDBID EVB
ID FETCH-epo_espacenet_WO2021030552A13
IEDL.DBID EVB
IngestDate Fri Sep 20 10:13:51 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_WO2021030552A13
Notes Application Number: WO2020US46113
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210218&DB=EPODOC&CC=WO&NR=2021030552A1
ParticipantIDs epo_espacenet_WO2021030552A1
PublicationCentury 2000
PublicationDate 20210218
PublicationDateYYYYMMDD 2021-02-18
PublicationDate_xml – month: 02
  year: 2021
  text: 20210218
  day: 18
PublicationDecade 2020
PublicationYear 2021
RelatedCompanies VERTEX PHARMACEUTICALS INCORPORATED
RelatedCompanies_xml – name: VERTEX PHARMACEUTICALS INCORPORATED
Score 3.3104692
Snippet Crystalline forms of Compound I: Formula (I) pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title CRYSTALLINE FORMS OF CFTR MODULATORS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210218&DB=EPODOC&locale=&CC=WO&NR=2021030552A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS8MwFD6MKeqbTsXplICjb8XVrF33MKRLG4bYZrSdzqfRKwgyh6v49z2Jne5pb8kJ5Abn8iUnXwC6eUYHeWph5FaWQx39LdWTXoKYhya2XVCMUBPF9hlYk1n_cW7OG_C-eQujeEK_FTkialSG-l4pe736P8RyVW7l-i59Q9HHA49HrlajY4lfUJ3d8cibClcwjTHEbVoQ_rZJdqt7B7HSngykJdO-9zyW71JW206FH8P-FPtbVifQKJYtOGSbv9dacODXV95YrLVvfQpdFr5GsYPwO_AIojc_IoITxuOQ-MKdPTmxCKMzuOVezCY6Drf4W93iRWzPjZ5DE3F_cQHEMkurzNAK9CRHEDXtQUJTIy8zY9hHudmGzq6eLnc3X8GRrMoEZMPuQLP6_Cqu0b9W6Y3alh866nkL
link.rule.ids 230,309,786,891,25594,76906
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFOebTsXp1IKjb8XVrB97GNKlLUXXZrSZzqfRTxBkDlfx3_dSO93T3sIdJJfA5e6X5H4B6GUpMbJEx8ytKIYKxluixP0YMQ-JTTMnmKHGFdtnoHuzweNcmzfgfVMLU_GEflfkiOhRKfp7We3Xq_9DLLt6W7m-S95Q9PHg8pEt1-hY4Bd0Z3s8cqbMZlSmFHGbHIS_OsFudW8hVtozBD-vSJ6ex6IuZbUdVNwj2J9if8vyGBr5sg0tuvl7rQ0Hfn3ljc3a-9Yn0KPha8QthN-BIyF68yOJuRJ1eSj5zJ5NLM7C6BRuXYdTT8HhFn-zW7ywbdvIGTQR9-fnIOlaoRcp7gJ9wRFENNOISaJmRaoOByjXOtDd1dPFbvUNtDzuTxZo8tMlHAqVeIysml1olp9f-RXG2jK5rpboBwwie_g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=CRYSTALLINE+FORMS+OF+CFTR+MODULATORS&rft.inventor=ZHOU%2C+Jinglan&rft.inventor=MEDEK%2C+Ales&rft.inventor=SWIFT%2C+Sara+E&rft.inventor=HADIDA+RUAH%2C+Sara+Sabina&rft.inventor=PARASELLI%2C+Prasuna&rft.inventor=MCCARTNEY%2C+Jason&rft.inventor=MILLER%2C+Mark+Thomas&rft.inventor=FRIEMAN%2C+Bryan&rft.inventor=ZWICKER%2C+Carl+L&rft.inventor=CLEVELAND%2C+Thomas&rft.inventor=WALDO%2C+Michael&rft.inventor=LU%2C+Jennifer&rft.inventor=PIERRE%2C+Fabrice&rft.inventor=ANDERSON%2C+Corey+Don&rft.inventor=LI%2C+Jicong&rft.inventor=COON%2C+Timothy+Richard&rft.inventor=GAGNON%2C+Kevin+J&rft.inventor=SHI%2C+Yi&rft.inventor=ZHANG%2C+Beili&rft.inventor=SHRESTHA%2C+Muna&rft.inventor=GROOTENHUIS%2C+Peter+%28deceased%29&rft.inventor=CLEMENS%2C+Jeremy+J&rft.date=2021-02-18&rft.externalDBID=A1&rft.externalDocID=WO2021030552A1